MarketResearch.biz has recently published its market research report titled, “Global Oral Biologics Market by Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, and Other Indications) and Region (US, Europe, Asia Pacific, Rest of the World) – Global Forecast from 2020 to 2029”. The report provides an in-depth analysis of the global oral biologics market. It is through exhaustive and systematic research efforts as well as ideal segmentation that the research results have been presented over the study period. In addition, the report provides the first five-year cumulative revenue (2020–2024), which is expected to be valued at over US$ 4 Billion, and this is projected to increase significantly over the latter part of the forecast period.
Oral biologics is a relatively innovative treatment designed for the treatment of inflammatory immune-mediated conditions. Oral biologics are vital for biologic administration – to make administration the same as a small molecule. The simplicity in the use of oral biologics makes it more convenient and compliant treatment. Biological products are usually administered through the parental route of administration. Oral biologics are a novel category of drugs used in the treatment of arthritis, ulcerative colitis, and others.
Browse the full “Global Oral Biologics Market By Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, And Other Indications) And Region (Us, Europe, Asia Pacific, Rest Of The World) – Global Forecast From 2020 To 2029” report at https://marketresearch.biz/report/oral-biologics-market/
Global Oral Biologics Market: Dynamics
Continuously increasing research and development activities for the development of oral biologics is another significant factor driving market growth. For example, Biocon Limited working on the development of insulin tregopil, oral prandial insulin for Type 2 diabetes. Also, the Massachusetts Institute of Technology (MIT) researchers developed an oral insulin drug capsule called SOMA in February for type 1 diabetes patients to replace insulin injections. A company called Oramed Pharmaceuticals from Israel is also engaged in research and development activities for the development of ORMD-0901 which is an oral GLP-1 analog capsule. Chronic diseases and conditions are continuously increasing in the world due to changes in societal behavior and ever-rising aging populace. Biologics are becoming popular in the treatment of Chronic Diseases due to its high effectiveness. Ease in the use of oral biologics further helping the demand for oral biologics to treat chronic diseases and conditions. Therefore, increasing incidences of chronic diseases is driving demand for biologics, thereby fueling target market growth.
The adoption rate of novel drugs is increasing with rising healthcare expenditure, and awareness is helping target market growth. Oral biologics are novel drugs used in the treatment of several diseases such as arthritis, diabetes, chronic disease, and more. Therefore, an increase in the adoption of the novel drug is expected to fuel target market growth.
Global Oral Biologics Market: Market Forecast
The comprehensive research report comprises a complete forecast of the global oral biologics market based on factors affecting the market and their impact in the foreseeable future. According to the forecast projections, revenue from the global oral biologics market is expected to expand at a CAGR of over 8.2% over the forecast period.
Global Oral Biologics Market: Segmental Snapshot
The market report has been segmented on the basis of indication and region. The indication segments include rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications. The regions covered in the analysis include the US, Europe, Asia Pacific, and the rest of the World.
By Indication: The rheumatoid arthritis segment is expected to account for highest revenue share contribution as compared to other indication segments, and is expected to register the highest CAGR of over 6.7% over the forecast period.
By Region: The market in the US accounted for the highest revenue share in the global oral biologics market. The market in the Asia Pacific is projected to register the highest CAGR of over 8.0% during the forecast period.
Global Oral Biologics Market: Competitive Analysis
The research report on the global Oral Biologics market includes profiles of some of the major companies such as Eli Lilly and Company, Pfizer Inc., AbbVie Inc., and Therapeutics and Gilead Sciences, Inc.
The Global Oral Biologics Market: Industry, Size, Share, Growth, Trends, and Forecast, 2020–2029 report has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global oral biologics market for 2019–2029.
No comments:
Post a Comment